Skip to main content
. Author manuscript; available in PMC: 2007 Nov 16.
Published in final edited form as: Cardiovasc Res. 2007 May 4;75(3):530–535. doi: 10.1016/j.cardiores.2007.04.022

Fig. 4.

Fig. 4

CYP-D-/- mice are resistant to pharmacological preconditioning and postconditioning. Infarct size (IS) expressed as a % of the area at risk (AAR) in wild-type (A) or Cyp-D-/- (B) mice receiving vehicle (VC) or diazoxide pretreatment or vehicle (VC), cyclosporin-A (CsA), sanglifehrin-A (SfA), bradykinin (Brady) at time of reperfusion (n=6-8/group). *P<0.01 vs. control.